Large Cap Biotech Analyst Fye and Major & Specialty Pharmaceuticals Analyst Schott discuss the viewpoint on Pfizer’s acquisition of Seagen on an Analyst/Industry conference call to be held on March 14 at 1 pm. Webcast Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities
- Seagen price target raised to $229 from $210 at Oppenheimer
- Seagen price target raised to $228 from $145 at Barclays
- Seagen downgraded to Market Perform from Outperform at JMP Securities